|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0011860,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0040808,
umls-concept:C0293359,
umls-concept:C0442027,
umls-concept:C0670129,
umls-concept:C0907402,
umls-concept:C1883712,
umls-concept:C2587213
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2008-10-21
|
|
pubmed:abstractText |
Injection of long-acting insulin at bedtime is a common therapeutic approach for patients with type 2 diabetes that is poorly controlled with oral regimens. Neutral protamine lispro (NPL) insulin has demonstrated better glycemic control and similar incidence of hypoglycemic events than that of neutral protamine Hagedorn insulin.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/Hemoglobin A, Glycosylated,
http://linkedlifedata.com/resource/pubmed/chemical/Hypoglycemic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin, Long-Acting,
http://linkedlifedata.com/resource/pubmed/chemical/Metformin,
http://linkedlifedata.com/resource/pubmed/chemical/Protamines,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfonylurea Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/glargine,
http://linkedlifedata.com/resource/pubmed/chemical/neutral protamine lispro
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1539-3704
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
21
|
|
pubmed:volume |
149
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
531-9
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:18936501-Administration, Oral,
pubmed-meshheading:18936501-Adult,
pubmed-meshheading:18936501-Aged,
pubmed-meshheading:18936501-Blood Glucose,
pubmed-meshheading:18936501-Diabetes Mellitus, Type 2,
pubmed-meshheading:18936501-Drug Therapy, Combination,
pubmed-meshheading:18936501-Female,
pubmed-meshheading:18936501-Hemoglobin A, Glycosylated,
pubmed-meshheading:18936501-Humans,
pubmed-meshheading:18936501-Hypoglycemia,
pubmed-meshheading:18936501-Hypoglycemic Agents,
pubmed-meshheading:18936501-Injections, Subcutaneous,
pubmed-meshheading:18936501-Insulin,
pubmed-meshheading:18936501-Insulin, Long-Acting,
pubmed-meshheading:18936501-Male,
pubmed-meshheading:18936501-Metformin,
pubmed-meshheading:18936501-Middle Aged,
pubmed-meshheading:18936501-Protamines,
pubmed-meshheading:18936501-Sulfonylurea Compounds,
pubmed-meshheading:18936501-Weight Gain
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
|
|
pubmed:affiliation |
Second University of Naples and Azienda Sanitaria Locale Napoli 5, Naples, Italy.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
